The Silent Risk of Sudan Virus: A Review Addressing Global Health Vulnerabilities

Sudan Virus Disease (SVD) is a deadly hemorrhagic fever caused by the Sudan virus, first discovered in Sudan in 1976. This disease has been linked to several outbreaks in sub-Saharan Africa, particularly in Uganda. The high fatality rate of SVD, ranging from 41% to 70%, emphasizes the critical need for effective preventive measures and treatments. This perspective piece focuses on the challenges faced by low-income countries in handling SVD, focusing on Uganda's 2025 epidemic and the ongoing global efforts to develop vaccines and therapies.

SVD spreads primarily through contact with the bodily fluids of infected individuals or animals. The disease's prolonged incubation period complicates early detection and containment. In resource-limited settings like Uganda, the healthcare system often struggles with inadequate infrastructure and personnel, hindering effective outbreak control. Cultural practices, such as burial rituals involving physical contact with the deceased, further exacerbate transmission. Despite advancements in monoclonal antibody treatments and vaccine development, these solutions are not yet widely available. The slow pace of clinical trials and logistical challenges prevent rapid deployment of these interventions. International collaboration is crucial to address these obstacles. By improving healthcare infrastructure, enhancing early detection systems, and ensuring equitable access to treatments, the global community can better respond to SVD outbreaks. Additionally, public education and cultural adaptation are vital in reducing transmission risks.

A comprehensive global strategy is needed to tackle SVD, with an emphasis on strengthening healthcare systems, accelerating vaccine development, and improving access to treatments in vulnerable regions. A coordinated response, with international support, can help mitigate future outbreaks and protect at-risk populations.